$HIMS

HIMS

Hims & Hers Health, Inc. Class A Common Stock

All takes and content in this window

As of 10-02
10-01
The Motley FoolPublished 2026-10-01
“The Truth About Hims & Hers Stock: A Deep Dive”
$HIMSNo side taken
HIMS is a high-risk speculative buy; huge TAM and >50% growth potential are balanced against strong competition, regulatory ambiguity, and margin compression risks.

Hims & Hers is one of the most talked-about stocks in the market. It is also one of the most volatile stocks . The stock has risen by 250% over the past five years , but if you look at it over the past year, the stock has fallen by about 50%. There's a lot going on inside the company.

09-25
09-18
Schwab NetworkPublished 2026-09-18
“40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"”
$HIMSBullish
HIMS is undervalued and poised for upside; its platform model captures value from any winning GLP-1 drug, and short-selling pressure will diminish as market cap grows.

I want to talk about the company "Hems & Hers Health". This is another name that is attracting a lot of attention, especially on social media. It's a volatile stock, but it seems to be in a transitional phase, and I'm interested to know your opinion on its role in this area, and your general opinion of the company .

09-16
Parkev Tatevosian, CFAPublished 2026-09-16
“Is Hims & Hers Stock a Buy Right Now in September? | HIMS Stock Analysis”
$HIMSBullish
HIMS is a buy for high-risk-tolerance long-term investors due to strong growth prospects and fair valuation.

Hims & Hers management team reiterated its longer-term guidance to investors. The management team is forecasting at least $6.5 billion in revenue by 2030 and $1.3 billion in adjusted earnings before interest, taxes, depreciation, and amortization.

But does this make Hims & Hers stock a buying opportunity for long-term investors? So, revenue of at least $6 billion by 2030 would be more than double their most recent trailing 12-month total.

In that period, Hims & Hers reported $2.6 billion in revenue. That's up from around $250 million in 2020. This has been one of the fastest-growing companies in the world.

Showing 4 / 4 on this page
See this ticker’s full history